Prognostic impact of coronary microvascular dysfunction assessed by caIMR in overweight with chronic coronary syndrome patients

Cailin Feng1, Fuad A. Abdu1, Abdul-Quddus Mohammed1, Wen Zhang1, Lu Liu1, Guoqing Yin1, Yundi Feng2, Ayman A. Mohammed1, Redhwan M. Mareai1, Xian Lv1, Tingting Shi1, Xuejing Yu1 and Wenliang Che1,3

1Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, 2RainMed Medical, Suzhou, China, 3Department of Cardiology, Shanghai Tenth People’s Hospital Chongming Branch, Shanghai, China

Objective: Coronary microvascular dysfunction (CMD) may associate with adverse cardiovascular events in obese patients. Coronary angiography-derived index of microcirculatory resistance (caIMR) is proposed as a less-invasive and pressure-wire-free index to assess CMD. We aimed to investigate the impact of coronary microvascular function assessed by caIMR in patients with overweight and chronic coronary syndrome (CCS).

Methods: CCS patients who underwent coronary angiography between 2015 to 2018 were included. Overweight was defined as BMI ≥ 24.0 kg/m². Impaired coronary microvascular function was defined as caIMR ≥ 25U. The patients were classified according to BMI and caIMR. The primary endpoint was major adverse cardiac events (MACE). Kaplan-Meier and Cox regression analyses evaluated the association between caIMR and MACE.

Results: Two hundred and eighty-two CCS patients were enrolled. Among these, 169 (59.93%) were overweight. Impaired coronary microvascular function was higher in overweight patients than in patients with normal weight (49.70% vs. 38.05%; P=0.035). During 35 months of follow-up, 33 MACE had occurred. Among the total CCS population, MACE was higher in patients with high caIMR than in low caIMR (18.11% vs. 6.45%, P=0.003). In subgroups analysis, MACE was higher in overweight patients with high caIMR than low caIMR (20.24% vs. 7.06%, P=0.014), while there were no significant differences in normal-weight patients. Multivariate Cox analysis demonstrated that caIMR≥25 was independently associated with MACE in overweight patients (HR, 2.87; 95% CI, 1.12–7.30; P=0.027) but not in the normal-weight patients. In addition, caIMR showed a significant predictive value for adverse outcomes in overweight patients and provided an incremental prediction when added to a prediction model with BMI.
Conclusions: Impaired coronary microvascular function assessed by calIMR was common and is an independent predictor of MACE in overweight patients with CCS.

KEYWORDS coronary microvascular dysfunction, coronary angiography-derived index of microcirculatory resistance, overweight, chronic coronary syndrome, clinical outcomes

Introduction

Obesity is one of the ongoing epidemics worldwide; the Global Burden of Disease group estimated that about 4 million deaths worldwide were related to high body mass index (BMI) (1). Obesity has been linked to chronic metabolic disorders such as coronary heart disease (CAD), hypertension, hyperlipidemia, diabetes mellitus, and various malignancies, resulting in poor clinical outcomes (2–6). The pathogenesis principles responsible for increased risk in obesity are complicated, including increased oxidative stress, enhanced sympathetic nervous system activity, and low-grade systemic inflammation, as they can lead to coronary microvascular dysfunction (CMD), which is, in turn, associated with increased adverse clinical outcomes (7–9).

CMD is recognized as increased blood flow in response to stress due to increased microvascular resistance or impaired microvascular dilatation, resulting in myocardial ischemia and increased cardiovascular risk (10). Clinical studies have found that CMD is more common and may associate with adverse cardiovascular events in obese individuals (8, 11, 12). A recent study showed that obese patients with CMD assessed by coronary flow reserve (CFR) have a 2.5-fold higher risk of developing clinical adverse events (11). This may imply a potential correlation between obesity, CMD, and poor clinical outcomes.

The evaluation of coronary microvascular function using invasive wire-derived techniques is predominantly governed by CFR and the index of microcirculatory resistance (IMR). The clinical utility of CFR to evaluate coronary microvascular function among obese patients has been shown in prior investigations, which reported that obese patients are associated with impaired CFR (8, 11). In contrast to CFR, IMR is more specific to the microvasculature, more quantitative, and is not influenced by hemodynamic changes or epicardial stenosis (13). IMR has previously been proven to have significant diagnostic and prognostic performance in various clinical disorders (14–16). However, owing to its invasive nature, longer procedure duration, higher cost, technical complexity, and the usage of adenosine to achieve maximal hyperemia, its use in clinical practice remains incredibly limited. Recently developed functional coronary angiography parameters enable simpler, rapid, and do not require pressure wire or adenosine, using coronary angiography derived index of microvascular resistance (calIMR) (17). Several clinical studies investigated the role of calIMR and concluded that calIMR is a valuable predictor and has a high diagnostic performance in different clinical settings, including coronary artery disease patients who received the percutaneous coronary intervention (PCI), ST-Segment elevation myocardial infarction (STEMI), and non-obstructive coronary arteries (18–21). Notably, there have been no investigations into the prognostic value of the IMR either invasively or non-invasively in obese patients.

Therefore, this study aimed to clarify the prognostic impact of coronary microvascular function derived by calIMR in overweight with chronic coronary syndrome (CCS) patients.

Methods

Study population

Between June 2015 and May 2018, CCS patients who have undergone coronary angiography for suspected angina at Shanghai Tenth People’s Hospital were enrolled in this single-center retrospective observational study.
The inclusion criteria of the present study were (1): Age ≥18 years old (2); Patients comply with the 2019 ESC guidelines for the diagnosis and management of CCS (22). Patients were excluded if they had a myocardial infarction (MI) within the previous 7 days, severe coagulopathy or bleeding disorders, malignant tumor and estimated life span less than one year, left ventricular ejection fraction<35%, and post coronary artery bypass graft surgery. The calMR exclusion criteria include: poor contrast opacification, serious vascular overlap or distortion of the target vessel, and poor angiographic image quality are insufficient to demonstrate the contour detection requested by the FLASH software.

The basic clinical information, past medical history, and laboratory data of all subjects in this study were documented. Electrocardiograms, echocardiograms and coronary angiography information were collected from all participants.

The study protocol was approved by the ethics committee of Shanghai Tenth People’s Hospital and was performed in compliance with the Declaration of Helsinki. Written informed consent was obtained from all patients.

**calMR measurement**

calMR was achieved using software with the Flash Angio system (including the Flash Angio console, Flash Angio software, and Flash Pressure transducer; Rainmed Ltd., Suzhou, China). The theory and details of the measurement of calMR were reported by Yong Huo’s team (17), as computed as follows: calMR = Pd\text{hyp} \frac{L}{V_{\text{diastole}}} calMR is the measurement of pressure at maximal hyperemia as described by the previous study (17); the microvascular resistance and flow velocity are proportional to that of hyperemia in diastole and are computed in a unit volume of myocardium distal to the L position at maximum hyperemia. calMR was achieved by following three steps. A: Construction of a 3D mesh network along the coronary vessel. B: The hyperemic aortic pressure is based on mean arterial pressure (MAP) at angiography; MAP x 0.2 when vessel. B; The hyperemic aortic pressure is based on mean steps. A; Construction of a 3D mesh network along the coronary maximum hyperemia. caIMR was achieved by following three

caIMR was achieved using software with the Flash Angio system (including the Flash Angio console, Flash Angio software, and Flash Pressure transducer; Rainmed Ltd., Suzhou, China). The theory and details of the measurement of calMR were reported by Yong Huo’s team (17), as computed as follows: calMR = Pd\text{hyp} \frac{L}{V_{\text{diastole}}} calMR is the measurement of pressure at maximal hyperemia as described by the previous study (17); the microvascular resistance and flow velocity are proportional to that of hyperemia in diastole and are computed in a unit volume of myocardium distal to the L position at maximum hyperemia. calMR was achieved by following three steps. A: Construction of a 3D mesh network along the coronary vessel. B: The hyperemic aortic pressure is based on mean arterial pressure (MAP) at angiography; MAP x 0.2 when vessel. B; The hyperemic aortic pressure is based on mean steps. A; Construction of a 3D mesh network along the coronary maximum hyperemia. caIMR was achieved by following three

The follow-up information was recorded by two trained cardiologists at Shanghai Tenth People’s Hospital by collecting medical and surgical records. All patients were followed up for 35 months through phone calls and outpatient visits. The primary clinical endpoints were the first major adverse cardiac events (MACE), including cardiovascular death, nonfatal MI, heart failure, and ischemia-driven revascularization. We defined cardiovascular death as death due to malignant arrhythmia, myocardial infarction, or refractory heart failure. Nonfatal MI was defined as the presence of typical symptoms of myocardial ischemia and observed dynamic variation of myocardial enzymes except death. Heart failure was defined as hospitalization due to acute or chronic heart failure in accordance with 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure (25). Ischemia-driven revascularization means the revascularization procedure which was caused by a positive test or the replace of angina pectoris.

**Statistical analysis**

The Statistical Package for Social Sciences (SPSS), version 22, was used to analyze the data of this study. GraphPad software, version 8.0.1, was used to create the figures. The data were
recorded as a percentage (%) for categorical variables and mean ± standard deviation (SD) or medians and interquartile ranges for continuous variables. The independent sample t-test or Mann–Whitney U test was used to compare numerical variables between groups. For categorical variables, the chi-square test and Fisher’s exact tests were used as appropriate. Kaplan-Meier analysis was used to compute MACE-free survival rates, and differences between the groups were assessed by the log-rank test. Cox regression models were used to derive adjusted hazard ratio (HR) to evaluate predictors of the clinical endpoints. The univariate analysis includes cardiac risk variables and parameters that were statistically significant at baseline between groups. Factors that were univariate predictors with P< 0.10 were incorporated into the multivariable models. Values are expressed as hazard ratio (HR) with a 95% confidence interval (CI). To assess the effect of caIMR on MACE between overweight and normal-weight groups, an interaction analysis was performed using a Cox regression model. The receiver operating characteristic (ROC) curve clarifies the prognostic value of caIMR in the overweight group. A further assessment of the incremental prognostic value of caIMR using integrated discrimination improvements (IDI) and net reclassification improvements (NRI) was performed. All the tests were two-sided, and a P-value< 0.05 was considered statistically significant.

### Result

#### Baseline characteristics

Baseline, biochemical and angiographic characteristics of the study population are shown in Tables 1, 2. Two hundred and eighty-two CCS patients were enrolled in the final analysis of the

| TABLE 1 Baseline characteristics. | Normal weight (n = 113) | Overweight (n = 169) | P-value |
|----------------------------------|------------------------|----------------------|---------|
| Demographics                     |                        |                      |         |
| Age (years)                      | 66.42 ± 9.22           | 63.97 ± 9.51         | 0.033   |
| Male, n (%)                      | 66 (58.41)             | 129 (76.33)          | 0.002   |
| Cardiovascular risk factors      |                        |                      |         |
| Diabetes history                 | 29 (25.66)             | 67 (39.64)           | 0.015   |
| BMI (kg/m²)                      | 22.49 (21.33-23.28)    | 26.45 (25.08-27.98)  | <0.01   |
| Hypertension history             | 74 (65.49)             | 125 (73.96)          | 0.126   |
| Hyperlipidemia history           | 19 (16.81)             | 40 (23.67)           | 0.166   |
| Atrial fibrillation history      | 5 (4.42)               | 9 (5.33)             | 0.787   |
| Post-PCI                         | 90 (79.65)             | 131 (77.51)          | 0.670   |
| Smoking history                  | 23 (20.35)             | 45 (26.63)           | 0.228   |
| Family history of CAD            | 4 (3.54)               | 8 (4.73)             | 0.768   |
| LVEF                             | 63.00 (60.00-65.00)    | 63.00 (60.00-65.00)  | 0.899   |
| Vital signs                      |                        |                      |         |
| Systolic blood pressure (mmHg)   | 130.11 ± 21.80         | 136.71 ± 20.30       | 0.010   |
| Diastolic blood pressure (mmHg)  | 73.31 ± 11.75          | 78.09 ± 11.63        | 0.001   |
| Heart rate                       | 73.00 (68.00-84.00)    | 76.00 (68.50-82.00)  | 0.144   |
| Biochemical parameters           |                        |                      |         |
| TG (mmol/L)                      | 1.19 (0.95-1.69)       | 1.46 (1.15-2.31)     | <0.01   |
| TC (mmol/L)                      | 3.47 (2.98-4.14)       | 3.56 (2.93-4.28)     | 0.759   |
| LDL-C (mmol/L)                   | 1.71 (1.40-2.28)       | 1.79 (1.34-2.41)     | 0.746   |
| HbA1c (g/L)                      | 6.00 (5.65-6.75)       | 6.30 (5.80-7.10)     | 0.002   |

Values are shown as n (%), mean ± SD, or medians (interquartile ranges). BMI: body mass index. PCI: percutaneous coronary intervention. LVEF: left ventricular ejection fraction. TG: triglycerides. TC: total cholesterol. LDL-C: high-density lipoprotein. HbA1c: glycated hemoglobin.

| TABLE 2 Coronary and angiographic characteristics. | Normal weight (n = 113) | Overweight (n = 169) | P-value |
|---------------------------------------------------|------------------------|----------------------|---------|
| Coronary Physiological parameters                 |                        |                      |         |
| caFFR                                            | 0.92 (0.91-0.95)       | 0.93 (0.90-0.95)     | 0.792   |
| caIMR                                            | 23.80 (19.10-30.75)    | 24.70 (19.25-34.50)  | 0.380   |
| caIMR≥25U                                         | 43 (38.05)             | 84 (49.70)           | 0.035   |
| Target vessel                                    | *n=123                 | *n=189               |         |
| LAD, n (%)                                       | 74 (60.16)             | 126 (66.67)          | 0.242   |
| LCX, n (%)                                       | 23 (18.70)             | 22 (11.64)           | 0.083   |
| RCA, n (%)                                       | 26 (21.14)             | 41 (21.69)           | 0.907   |

Values were shown as n (%) or medians (interquartile ranges). caFFR: coronary angiography-derived fractional flow reserve. caIMR: coronary angiography-derived index of microcirculatory resistance; LAD: left anterior descending; LCX: left circumflex; RCA: right coronary artery. *n of target vessel is total number of left anterior descending = 200, left circumflex = 45 and right coronary artery = 67.
present study, with a mean age of 64.95 ± 9.46 years. Among these, 169 (59.93%) patients had overweight, while 113 (40.07%) were of normal weight (Figure 1). Compared to the normal weight group, patients in the overweight group had a higher rate of male patients, diabetes mellitus, systolic blood pressure, diastolic blood pressure, triglycerides, and HbA1c, while patients in the normal weight were older. The proportion of impaired coronary microvascular function (calMR≥25) was higher in overweight patients than in patients with normal weight (49.70% vs. 38.05%; P=0.035). The distribution of other demographic, baseline information, and angiographic characteristics were similar between the two groups.

Three hundred and twelve coronary arteries were assessed in this study: left anterior descending artery (LAD), n = 200 (64.10%); left circumflex artery (LCX), n = 45 (14.42%); and right coronary artery (RCA), n = 67 (21.47%).

Clinical outcomes

During 35 months of follow-up, a total of 33 MACE have occurred. The incidence rate of MACE was higher in the high calMR group than in the low calMR group (18.11% vs. 6.45%, P=0.003). In subgroups analysis, the more apparent differences only appear in the overweight group with high calMR; that is, the rate of MACE in the overweight patients with high calMR is higher than in the low calMR patients (20.24% vs. 7.06%, P=0.014). However, there were no differences in the normal weight group between high and low calMR patients (13.95% vs. 5.71%, P=0.176) (Table 3).

Through survival-free analysis of composite MACE, the Kaplan-Meier curves display that patients with high calMR had a significantly increased risk of MACE than low calMR in total populations (log-rank P = 0.001) (Figure 2A). Likewise, when only ischemia-driven revascularization and heart failure were analyzed separately, patients with high calMR still had a higher risk of MACE than low calMR patients (log-rank P = 0.031, and log-rank P=0.004, Figures 2B, C). The same results were only noted among high and low calMR in overweight patients (log-rank P=0.011) (Figure 3). However, this difference was not apparent among the normal-weight group (log-rank P=0.088) (Figure 4).

Outcome predictors

Tables 4, 5 displayed the impact of potential risk factors on the risk of MACE across subgroups through univariate and multivariate analyses. Univariate Cox regression analysis identified calMR≥25 as a significant predictor of MACE in total CCS patients (HR, 3.19; 95% CI, 1.52-6.71; P=0.002). It is worth noting that this relationship was only found in patients with overweight rather than normal-weight patients (HR, 3.16; 95% CI, 1.24-8.01; P=0.016). Multivariate Cox regression analysis showed that calMR≥25 is still independently associated with an increased hazard of MACE in patients with overweight even after adjusting for other confounding factors.

TABLE 3 Clinical Outcomes by calMR and BMI.

|                  | Total | Normal weight | Overweight |
|------------------|-------|---------------|------------|
| calMR< 25 (n = 155) |       | calMR ≥ 25 (n = 127) | P-value | calMR< 25 (n = 70) | calMR ≥ 25 (n = 43) | P-value | calMR< 25 (n = 85) | calMR ≥ 25 (n = 84) | P-value |
| MACE             | 10 (6.45) | 23 (18.11) | 0.003 | 4 (5.71) | 6 (13.95) | 0.176 | 6 (7.06) | 17 (20.24) | 0.014 |
| Cardiac death    | 1 (0.65) | 0 | 1.000 | 0 | 0 | – | 1(1.18) | 0 | 1.000 |
| Revascularization| 6 (3.87) | 12 (9.45) | 0.084 | 2 (2.86) | 3 (6.98) | 0.367 | 4(4.71) | 9 (10.71) | 0.161 |
| Nonfatal MI       | 2 (1.29) | 3 (2.36) | 0.660 | 1 (1.43) | 3 (6.98) | 0.153 | 1(1.18) | 3 (3.57) | 0.368 |
| Heart failure     | 1 (0.65) | 8 (6.30) | 0.012 | 1 (1.43) | 3 (6.98) | 0.153 | 0 | 5 (5.95) | 0.029 |

Values were shown as n (%). MACE, major adverse cardiac events; calMR, coronary angiography-derived index of microcirculatory resistance; MI, myocardial infarction.
risk factors (HR, 2.87; 95% CI, 1.12-7.30; P=0.027). Notably, there was a significant effect of the interaction term of calMR ≥ 25 in predicting MACE between overweight and normal-weight groups (P = 0.002 for interaction). Diabetes was also a predictor of MACE, either in univariate or multivariate analysis in our study.

The incremental predictive value of calMR

The ROC curve analysis showed that calMR could provide a significant predictive value for MACE in patients with overweight, with a sensitivity of 0.739 and specificity of 0.623 (95% CI 0.523-0.764, P = 0.027) (Figure 5). Additional analysis was performed to examine whether calMR had an incremental predictive ability for MACE in overweight patients (Table 6). The results showed that calMR, when added to a model with BMI, the combined model was able to predict adverse outcomes with more accuracy and provided significant improvement in the IDI (4.3, 95% CI: 0.1-12.3, p = 0.020) and NRI (32.8, 95% CI: 0.0-55.4, p = 0.020).

Discussion

The present investigation is the first to evaluate the prognostic value of the coronary microvascular function in overweight with CCS patients reflected by the less-invasive and pressure-wire-free calMR index. The major findings of the
The present study were: 1) impaired coronary microvascular function was more common among overweight with CCS; 2) high calMR was associated with worsening clinical outcomes, as well as had good diagnostic and prognostic performance in CCS patients with overweight. Our findings provide valuable insight into the impact of calMR on overweight patients, given its less invasiveness, pressure-wire-free design, and no hyperemic agents.

Several epidemiologic studies have investigated the relationship between obesity, overweight, and adverse clinical outcomes (26, 27). Obesity has been implicated in increased systemic vascular resistance and increased risk of cardiovascular...

| TABLE 4 Univariate analysis for MACE. |
|--------------------------------------|
| **Total**                            | **Normal weight** | **Overweight** |
| **HR (95% CI)**                      | **P**             | **HR (95% CI)** | **P** |
| Age                                  | 1.02 (0.98-1.06)  | 0.313           | 1.02 (0.95-1.10) | 0.606 |
| Male                                 | 2.18 (0.90-5.29)  | 0.084           | 3.11 (0.66-14.66) | 0.152 |
| Diabetes                             | 2.68 (1.35-5.35)  | 0.005           | 4.48 (1.26-15.87) | 0.020 |
| SBP                                  | 1.00 (0.99-1.02)  | 0.803           | 0.99 (0.97-1.02)  | 0.617 |
| DBP                                  | 1.00 (0.97-1.03)  | 0.831           | 0.97 (0.92-1.02)  | 0.270 |
| HbA1c                                | 0.88 (0.61-1.27)  | 0.494           | 0.61 (0.17-2.24)  | 0.456 |
| calMR≥25                             | 0.99 (0.75-1.30)  | 0.919           | 0.62 (0.39-1.74)  | 0.615 |
|                                      | 3.19 (1.52-6.71)  | 0.002           | 2.87 (0.81-10.19) | 0.103 |

Univariate analysis enrolled factors with a P-value< 0.05 in the baseline. calMR, coronary angiography–derived index of microcirculatory resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HbA1c, glycated hemoglobin; HR, hazard ratio; CI, confidence interval.

| TABLE 5 Multivariate analysis for MACE. |
|----------------------------------------|
| **Total**                              | **Normal weight** | **Overweight** |
| **HR (95% CI)**                        | **P-value**       | **HR (95% CI)** | **P-value** |
| calMR≥25                               | 2.75 (1.29-5.85)  | 0.009           | 4.48 (1.26-15.87) | 0.487 |
| Diabetes                               | 2.23 (1.10-4.49)  | 0.025           | 2.87 (1.12-7.30)  | 0.027 |

Multivariate analysis adjusted for factors with a P-value< 0.1 in univariate analysis. calMR, coronary angiography–derived index of microcirculatory resistance; HR, hazard ratio; CI, confidence interval.
conditions (27, 28). Prior studies have shown that patients with central obesity are at an increased risk of atherosclerosis and poor clinical outcomes (29, 30). A study by Hubert et al. discovered that obesity is an independent risk factor for cardiovascular disease after 26-year of follow-up (31). High BMI was associated with a significantly increased risk of death among more than one million participants recruited in Asia (6). An elevated BMI is also strongly linked to an increased mortality rate, according to the largest cohort study with 363,2674 participants (32).

Besides microvascular angina, CMD is also involved in several cardiac and systemic diseases; emerging evidence suggests a pathogenic role of cardiovascular risk factors such as diabetes, hypertension, metabolic syndrome, and obesity in the pathogenesis of CMD (33, 34). CMD has recently been found to be more common in obese patients. An investigation using 13N-ammonia PET-MPI reported that 43.2% of non-centrally obese patients and 53.7% of centrally obese patients had CMD (12). Lee et al. reported that high IMR was associated with obesity, history of MI, right coronary artery, and female sex, suggesting that obese patients are more likely to have CMD (35). Myocardial blood flow was significantly reduced in obese and overweight individuals with normal metabolism, suggesting impaired coronary microcirculatory function (9). The interaction mechanism between obesity and CMD has been reported in previous studies indicating that adipose tissue deposition can lead to tissue hypoxia, which leads to an increase in cytokines such as leptin and interleukin-6; these adipokines and pro-inflammatory cytokines result in oxidative stress response that may lead to endothelial and microvascular dysfunction (36). In our study, we found that impaired coronary microvascular function was more common among CCS patients with overweight than normal-weight patients, which was in line with previous studies that indicate that CMD is more common among obese individuals.

As previous studies reported, CMD is closely linked with adverse cardiovascular events in multiple diseases (37, 38). The potential risk of CMD-related adverse events extends beyond obstructive coronary artery disease to risk factors such as obesity (11, 39). CMD increases in severity with increasing BMI and is a potential determinant of future cardiovascular disease risk than BMI or established risk factors (11). In a long-term study among obese patients with normal perfusion, Bajaj et al. reported that CMD was an independent predictor of adverse events, while reduced CFR was associated with a 2.5-fold increased risk of events (11). Our study extends the results of previous studies and found that the incidence of MACE in overweight patients with CMD was significantly higher than that in non-CMD patients, while there were no significant differences in normal-weight patients.

The coronary microvascular function can be assessed either invasively or using noninvasive methods, depending on the clinical situation (40). Among the invasive techniques, CFR and IMR are widely used wire-based measures of coronary microvascular function (16, 40). Invasive IMR as a quantitative assessment of the hyperemic microvascular resistance has shown better reproducibility even in patients with CCS (41). Earlier studies showed that IMR is a better indicator of impaired microvascular function than other measures among various patient populations, including patients with the acute coronary syndrome (42). Notably, in a multicenter prospective study among CAD patients, Lee et al. reported that obesity was strongly associated with high IMR, which suggests that obesity is potentially linked with CMD and cardiovascular risk (35). Although invasive IMR is a strong predictor of short and long-term cardiac events, unfortunately, due to some practical limitations, its use has been limited mainly due to IMR requiring coronary pressure-sensor guidewires and

![FIGURE 5](image_url)

**FIGURE 5** Receiver operating characteristic curves of calMR for predicting adverse events in overweight patients. AUC, area under the curve; CI, confidence interval.

| BMI | AUC (95% CI) | IDI (95% CI) | p value | NRI (95% CI) | p value |
|-----|--------------|--------------|---------|--------------|---------|
| BMI | 0.57 (0.47-0.67) | Reference | 0.020 | 32.8 (0.0-55.4) | 0.020 |
| BMI + calMR | 0.66 (0.57-0.76) | 4.3 (0.1-12.3) | Reference | |

AUC, Area under curve; IDI, Integrated discrimination improvement; NRI, Net reclassification index; CI, confidence interval; BMI, body mass index; calMR, coronary angiography derived index of microcirculatory resistance.
adenosine-induced hyperemia, complex operation, high cost, and long measurement time. caIMR is a new simple technique for assessing the state of the coronary microcirculation without a coronary guidewire and pharmacologic hyperemia (17). Several studies in different patient populations have reported good diagnostic and prognostic ability of calMR. In a recent study among patients with non-obstructive coronary artery disease, calMR significantly correlated with IMR to diagnose microcirculatory dysfunction (17). Choi et al. showed that the calMR was significantly associated with adverse cardiac events in STEMI patients (19). In patients with CAD, Dai N et al. (21) reported that calMR measured after PCI predicts the risk of cardiac death or readmission due to heart failure. Our recent study also found that calMR had an excellent prognostic ability for MACE among myocardial infarction with non-obstructive coronary arteries (MINOCA) patients (20). Among acute coronary syndromes and stable CAD, Scarsini et al. demonstrated similar findings and reported that calMR correlated well with IMR to predict microvascular obstruction (43). However, the prognostic impact of IMR among obese patients has not been investigated, regardless of invasive or non-invasive. To the best of our knowledge, the present study is the first to evaluate the prognostic significance of calMR in overweight patients. Our study found that a high calMR is an independent predictor for worse clinical outcomes in overweight patients but not in patients with normal weight. Importantly, patients with high calMR had a significantly higher rate of adverse events than patients with low calMR. Notably, there was a significant effect of the interaction term of high calMR in predicting MACE between overweight and normal-weight groups; this result better supports our conclusion that calMR≥25 was associated with an increased risk of MACE only in overweight patients but not in normal-weight patients. Further research studies with a large sample size are needed to confirm the present study’s findings.

Taken together, the findings of the present investigation are of significant clinical interest, which highlight a population at higher risk for overt cardiac dysfunction and adverse prognosis. calMR may provide additional information on high-risk individuals and help manage or prevent adverse outcomes. Meanwhile, calMR could potentially reduce the use of a pressure wire, reduce technical error, and enhance the adoption of physiological assessment of coronary microvascular function.

Limitations

Several limitations were presented in this study. First, this was a single-center study, and on account of the small sample size, the findings may not be generalizable to a broad population. Second, calMR was measured based on the angiography-derived diastolic flow velocity in contrast-induced sub-hyperemia. Third, in this study, we employed BMI≥24.0kg/m² to identify overweight among Chinese populations; thus, the findings of our study may not apply to populations of different ethnic backgrounds with body surface area; future studies are required to evaluate the association between calMR and outcomes in overweight patients using different definitions. Fourth, the longer follow-up and the comparison before and after regular pharmacotherapy or bariatric surgery need further examination. In addition, in our study, we did not measure more indicators that reflect the fat distribution.

Conclusion

Impaired coronary microvascular function assessed by calMR was common and is an independent predictor of MACE among overweight patients with CCS. The evaluation of calMR can provide an objective risk stratification method for patients with overweight and could potentially enhance the adoption of physiological assessment of coronary microvascular function.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Shanghai Tenth People’s Hospital, Tongji University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

CF, FA, XY and WC designed the study. WZ, LL, AQM, and GY collected the data. CF, FA, FY, AAM, RMM, XL, TS, YX and WZ were involved in data cleaning, follow-up, and verification. CF, FA, and WC drafted the manuscript and revised it critically for important intellectual content. WC and XY approved the final version of the manuscript. All authors contributed to manuscript revision, read, and approved the final version.
Funding

This work was supported by Chinese National Natural Science Foundation (82170521), Shanghai Natural Science Foundation of China (21ZR1449500), Foundation of Shanghai Municipal Health Commission (202140263), the Fundamental Research Funds for Central Universities (NO.22120190211), Foundation of Chongming (CKY2021-21, CKY2020-29), Clinical Research Plan of Shanghai Tenth People’s Hospital (YNCR2A001), and Clinical Research Plan of SHDC (SHDC2020CR4065).

Acknowledgments

Those who contributed to this work and met the authorship criteria are listed as authors of this manuscript.

References

1. Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estein K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med (2017) 377(1):13–27. doi: 10.1056/NEJMoa1614362
2. Ni Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M. Body mass index and cardiovascular disease in the Asia-pacific region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol (2004) 33(4):751–8. doi: 10.1093/ije/dyh163
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 371(9612):569–78. doi: 10.1016/S0140-6736(08)60269-x
4. Prospective Studies C. Body mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 373(9669):1088–96. doi: 10.1016/S0140-6736(09)60318-4
5. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 377(9777):1085–95. doi: 10.1016/S0140-6736(11)60105-9
6. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body mass index and risk of death in more than 1 million americans. N Engl J Med (2011) 364(18):719–29. doi: 10.1056/NEJMoa110679
7. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur J Heart J (2011) 32(11):1369–76. doi: 10.1093/euheartj/eth029
8. Tona F, Serra R, Di Accenzo L, oste E, Scarda A, Fabris R, et al. Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease. Nutr Metab Cardiovasc Dis (2014) 24(4):447–53. doi: 10.1016/j.numecd.2013.09.021
9. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Trans Res (2017) 183:57–70. doi: 10.1016/tr.2017.01.001
10. Shimokawa H, Suda A, Takahashi J, Berry C, Camici PG, Crea F, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the coronary vasomotor disorders international study (COVADIS) group. Eur Heart J (2021) 42(44):4592–600. doi: 10.1093/eurheartj/ehab382
11. Baijs NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol (2018) 72(7):707–17. doi: 10.1016/j.jacc.2018.05.049
12. Wang R, Li X, Huangfu S, Yao Q, Wu P, Wu Z, et al. Combining body mass index with waist circumference to assess coronary microvascular function in patients with non-obstructive coronary artery disease. J Nucl Cardiol (2021). doi: 10.1097/HJCI.0000000000001988
13. Pagonas N, Gross CM, Li M, Bondke A, Klaus V, Buschmann EE. Influence of epicardial stenosis severity and central venous pressure on the index of microcirculatory resistance in a follow-up study. EuroIntervention (2014) 9(9):1063–8. doi: 10.4244/EIJV9A180
14. Ahn SG, Hung OY, Lee JW, Lee JH, Youn YJ, Ahn MS, et al. Combination of the thermodilution-derived index of microcirculatory resistance and coronary flow reserve is highly predictive of microvascular obstruction on cardiac magnetic resonance imaging after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2016) 9(8):793–801. doi: 10.1016/j.jcin.2015.12.025
15. Fahmi G, Wolfrum M, De Maria GL, Cuculi F, Dawkins S, Alkhali M, et al. Index of microcirculatory resistance at the time of primary percutaneous coronary intervention predicts early cardiac complications: Insights from the OnAMI (Oxford study in acute myocardial infarction) cohort. J Am Heart Assoc (2017) 6(11):e005409. doi: 10.1161/JAHA.116.005409
16. Fearon WF, Kobayashi Y. Invasive assessment of the coronary microvasculature: The index of microcirculatory resistance. Circ Cardiovasc Interv (2017) 10(12):e005361. doi: 10.1161/CIRCINTERVENTIONS.117.005361
17. Ai H, Feng YD, Gong YJ, Zheng B, Jin QH, Zhang HP, et al. Coronary angiography-derived index of microvascular resistance. Front Physiol (2020) 11:605356. doi: 10.3389/fphys.2020.605356
18. Kotronias RA, Terentes-Printzios D, Shanmuganathan M, Marin F, Scarsini R, Bradley-Watson J, et al. Long-term clinical outcomes in patients with an acute ST-Segment-Elevation myocardial infarction stratified by angiography-derived index of microcirculatory resistance. Front Cardiovasc Med (2021). doi: 10.3389/fcvm.2021.717114
19. Choi KH, Dai N, Li YL, Kim JH, Shin D, Lee SH, et al. Functional coronary angiography-derived index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. JACC Cardiovascular Interventions (2021) 14(15):1670–84. doi: 10.1016/j.jcin.2021.05.027
20. Abdu FA, Liu L, Mohammed AQ, Yin G, Xu B, Zhang W, et al. Prognostic impact of coronary microvascular dysfunction in patients with myocardial infarction with non-obstructive coronary arteries. Eur J Intern Med (2021) 92:79–85. doi: 10.1016/j.ejim.2021.05.027
21. Dai N, Che WL, Liu L, Zhang W, Yin GQ, Xu B, et al. Diagnostic value of angiography-derived IMR for coronary microcirculation and its prognostic implication after PCI. Front Cardiovasc Med (2021) 8:735743. doi: 10.3389/fcvm.2021.735743
22. Knutti J, Wiens W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J (2020) 41(1):407–77. doi: 10.1093/eurheartj/ehaa225

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
23. Wang H, Zhai F. Programme and policy options for preventing obesity in China. Obes Rev (2013) 14:134–40. doi: 10.1111/obr.12106

24. American Diabetes A. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care (2020) 43(Suppl 1):S14–31. doi: 10.2337/dc20-S002

25. Authors/Task Force M, McDonagh TA, Metra M, Adamo M, Gardiner RS, BuembaC A, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail (2022) 24(1):4–131. doi: 10.1002/ejhf.2333

26. Haslam DW, James WPT. Obesity. Lancet (2005) 366(9492):1197–209. doi: 10.1016/S0140-6736(05)67483-1

27. Fox KAA, Despres JP, Richard AJ, Brette S, Deanfield JE, Comm IS, et al. Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91 246 ambulant patients in 27 European countries. Eur Heart J (2009) 30(24):3055–63. doi: 10.1093/eurheartj/ehp371

28. Mckegue PM, Shah B, Marmot MG. Relation of central obesity and cardiovascular risk in south asians. Lancet (1991) 337(8738):382–6. doi: 10.1016/0140-6736(91)91164-P

29. Valenta I, Dibiazin V, Quercioli A, Jungling FD, Ambrosio G, Wahl R, et al. Impact of obesity and bariatric surgery on metabolism and coronary circulatory function. Curr Cardiol Rep (2014) 16(1):433. doi: 10.1007/s11886-013-0438-3

30. Parikh NH, Keyes MJ, Larson MG, Pou KM, Hamburg NM, Vita JA, et al. Visceral and subcutaneous adiposity and brachial artery vasodilator function. Obes (Silver Spring) (2009) 17(11):2054–61. doi: 10.1038/oby.2009.60

31. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26 year follow-up of participants in the Framingham heart study. Circulation (1983) 67(5):968–74. doi: 10.1161/01.Cir.67.5.968

32. Bhaskaran K, dos Santos Silva I, Leon DA, Douglas JJ, Smeeth L. Association of BMI with overall and cause-specific mortality: A population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol (2018) 6(12):944–55. doi: 10.1016/S2213-8587(18)30288-2

33. Sucato V, Novo G, Saladinò A, Eveda S, Galassi AR. Coronary microvascular dysfunction: the index of microcirculatory resistance as a novel pressure-wire free tool to assess coronary microvascular dysfunction in acute coronary syndromes and stable coronary artery disease. Int J Cardiovasc Imaging (2021) 37(6):1801–13. doi: 10.1007/s10554-021-02254-8

34. Sucato V, Novo G, Saladinò A, Rubino M, Caronna N, Luparelli M, et al. Ischemia in patients with no obstructive coronary artery disease: classification, diagnosis and treatment of coronary microvascular dysfunction. Coron Artery Dis (2020) 31(5):472–6. doi: 10.1097/MCA.0000000000000855

35. Lee JM, Layland J, Jung JH, Lee HI, Echavarria-Pinto M, Watkins S, et al. Integrated physiologic assessment of ischemic heart disease in real-world practice using index of microcirculatory resistance and fractional flow reserve: Insights from the international index of microcirculatory resistance registry. Cire Cardiovasc Interv (2015) 8(11):e002857. doi: 10.1161/CIRCINTERVENTIONS.115.002857

36. Bagi Z, Brokova Z, Feher A. Obesity and coronary microvascular disease - implications for adipose tissue-mediated remote inflammatory response. Curr Vasc Pharmacol (2014) 12(3):453–61. doi: 10.2174/1570161112666140423221843

37. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med (2007) 356(8):830–40. doi: 10.1056/NEJMra061889

38. Chilian WM. Coronary microcirculation in health and disease. summary of an NHLBI workshop. Circulation (1997) 95(2):522–8. doi: 10.1161/01.CIR.95.2.522

39. Tauceti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC, state-of-the-Art review. J Am Coll Cardiol (2018) 72(21):2625–41. doi: 10.1016/j.jacc.2018.09.042

40. Ong P, Saddar B, Seitz A, Hubert A, Beltrame JF, Prescott E. Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovasc Res (2020) 116(4):841–55. doi: 10.1093/cvr/cvra2339

41. Kodeboina M, Nogumo S, Munhoz D, Sonck J, Mileva N, Gallinoro E, et al. Simplified assessment of the index of microvascular resistance. J Interv Cardiol (2021) 34(6):560–5. doi: 10.1111/jict.12658

42. Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2008) 51(5):560–5. doi: 10.1016/j.jacc.2007.08.062

43. Scirrini R, Shamuganathan M, Kotronics RA, Terentes-Preziioso D, Borlotti A, Langrish JP, et al. Angiography-derived index of microcirculatory resistance (IMRangi) as a novel pressure-wire-free tool to assess coronary microvascular dysfunction in acute coronary syndromes and stable coronary artery disease. Int J Cardiovasc Imaging (2021) 37(6):1801–13. doi: 10.1007/s10554-021-02254-8